Approximately 10% of EGFR-activating mutations occur as in-frame insertion mutations in
exon 20 of the EGFR kinase domain (EGFR ins20). EGFR ins20 mutations have not …

Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Background Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer
(NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth …

The Epidermal growth factor receptor (EGFR) exon (ex) 20 insertions (ins) has been
considered as an “undruggable target” for a long time, with platinum-pemetrexed …

Afatinib, the world's first irreversible ErbB family (containing four different cancer cell
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …

Amivantamab is a bispecific antibody that recognizes epidermal growth factor receptor
(EGFR) and MET proto-oncogene (MET). In May 2021, the Food and Drug Administration …

Cancer Research, Statistics, and Treatment/Volume 5/Issue 1/January-March 2022 all EGFR‑
mutant non‑small cell lung cancers (NSCLCs). They are mutually exclusive of other known …

Background EGFR exon 20 insertion (EGFR ex20ins) mutations account for about 10–12%
of all EGFR-mutated tumors, which are usually associated with primary drug resistance to …

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion
mutations: narrative review - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

表皮生长因子受体外显子20 插入(epidermal growth factor receptor exon 20 insertion, EGFR
ex20ins) 突变在非小细胞肺癌(non⁃ small cell lung cancer, NSCLC) 中被认为是“不可治疗的 …